Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05308446 · ClinicalTrials.gov registry record · Phase 2
Testing the Addition of Nivolumab to Standard Treatment for Patients With Metastatic or Unresectable Colorectal Cancer That Have a BRAF Mutation
A Phase 2 study of Stage III Rectal Cancer AJCC v8 and Stage III Colon Cancer AJCC V8, sponsored by National Cancer Institute (NCI).
- Active
- Registry status
- Phase 2
- Development phase
- 84
- Enrollment target
- 20
- Study locations
NCT05308446 is a Phase 2 study of Stage III Rectal Cancer AJCC v8 and Stage III Colon Cancer AJCC V8 that is active but no longer recruiting, run by National Cancer Institute (NCI). The registered enrollment target is 84 participants, below the 111-participant average among 15 other Stage III Rectal Cancer AJCC v8 trials with a reported enrollment target (24% lower). The trial reports 20 study locations across 2 states.
The verdict
NCT05308446, a Phase 2 study of Stage III Rectal Cancer AJCC v8 and Stage III Colon Cancer AJCC V8, is active but no longer recruiting, sponsored by National Cancer Institute (NCI).
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 84 participants
- Enrollment target
- 20
- Study locations
Study Summary
This phase II trial tests whether adding nivolumab to the usual treatment (encorafenib and cetuximab) works better than the usual treatment alone to shrink tumors in patients with colorectal cancer that has spread to other places in the body (metastatic) or that cannot be removed by surgery (unresectable) and whose tumor has a mutation in a gene called BRAF. Encorafenib is in a class of medications called kinase inhibitors. It is used in patients whose cancer has a certain mutation (change) in the BRAF gene. It works by blocking the action of mutated BRAF that signals cancer cells to multiply. This helps to stop or slow the spread of cancer cells. Cetuximab is in a class of medications called monoclonal antibodies. It binds to a protein called EGFR, which is found on some types of cancer cells. This may help keep cancer cells from growing. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving nivolumab in combination with encorafenib and cetuximab may be more effective than encorafenib and cetuximab alone at stopping tumor growth and spreading in patients with metastatic or unresectable BRAF-mutant colorectal cancer.
Conditions Studied
Interventions
- BIOLOGICAL Cetuximab
- BIOLOGICAL Nivolumab
- DRUG Encorafenib
Study Locations (20)
California
- Mercy Cancer Center - Carmichael - Carmichael
- Mercy San Juan Medical Center - Carmichael
- Kaiser Permanente Dublin - Dublin
- Mercy Cancer Center - Elk Grove - Elk Grove
- Kaiser Permanente-Fremont - Fremont
- Kaiser Permanente-Fresno - Fresno
- UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care - Irvine
- Kaiser Permanente-Modesto - Modesto
- Kaiser Permanente-Oakland - Oakland
- UC Irvine Health/Chao Family Comprehensive Cancer Center - Orange
- Mercy Cancer Center - Rocklin - Rocklin
- Kaiser Permanente-Roseville - Roseville
- Kaiser Permanente Downtown Commons - Sacramento
- Mercy Cancer Center - Sacramento - Sacramento
- Kaiser Permanente-South Sacramento - Sacramento
- Kaiser Permanente-San Francisco - San Francisco
- Kaiser Permanente-Santa Teresa-San Jose - San Jose
- Kaiser Permanente San Leandro - San Leandro
- Kaiser Permanente Medical Center - Santa Clara - Santa Clara
Arizona
- CTCA at Western Regional Medical Center - Goodyear
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 84 participants |
| Start Date | 2022-07-19 |
| Est. Completion | 2026-02-28 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05308446
The ClinicalTrials.gov registry entry for NCT05308446 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 84 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 111-participant average among 15 other Stage III Rectal Cancer AJCC v8 trials with a reported enrollment target (24% lower). The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 8 conditions, with Stage III Rectal Cancer AJCC v8 appearing as the primary indexed condition, and to 3 interventions - of which Cetuximab is the first listed.
NCT05308446 reports 20 study locations spanning 2 distinct geographic areas - top geographies include California, Arizona.
Frequently Asked Questions
What is clinical trial NCT05308446 about?
NCT05308446 is a clinical study titled "Testing the Addition of Nivolumab to Standard Treatment for Patients With Metastatic or Unresectable Colorectal Cancer That Have a BRAF Mutation". This phase II trial tests whether adding nivolumab to the usual treatment (encorafenib and cetuximab) works better than the usual treatment alone to shrink tumors in patients with colorectal cancer that has spread to other places in the body (metastatic) or that cannot be removed by surgery (unresec...
What is the current status of trial NCT05308446?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 84 participants. The study started on 2022-07-19. Estimated completion is 2026-02-28.
What conditions does trial NCT05308446 study?
This clinical trial studies the following conditions: Stage III Rectal Cancer AJCC v8, Stage III Colon Cancer AJCC V8, Metastatic Rectal Adenocarcinoma, Metastatic Colon Adenocarcinoma, Stage IV Colon Cancer AJCC v8.
What interventions are being tested in trial NCT05308446?
The interventions under investigation include: Cetuximab (BIOLOGICAL), Nivolumab (BIOLOGICAL), Encorafenib (DRUG).
Who is sponsoring clinical trial NCT05308446?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05308446 being conducted?
This trial has 20 study locations across Arizona, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Stage III Rectal Cancer AJCC v8
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Therapy Adapted for High Risk and Low Risk HIV-Associated Anal Cancer
RECRUITING · Phase 2
-
FOLFOX, Botensilimab, and Balstilimab for the Treatment of Localized Rectal Cancer Before Surgery
RECRUITING · Phase 2
-
Testing Nivolumab and Ipilimumab With Short-Course Radiation in Locally Advanced Rectal Cancer
ACTIVE NOT RECRUITING · Phase 2
-
Testing the Addition of an Anti-Cancer Drug, Irinotecan, to the Standard Chemotherapy Treatment (FOLFOX) After Long-Course Radiation Therapy for Advanced-Stage Rectal Cancers to Improve the Rate of Complete Response and Long-Term Rates of Organ Preservation
ACTIVE NOT RECRUITING · Phase 2
-
Panitumumab, Regorafenib, or TAS-102, in Treating Patients With Metastatic and/or Unresectable RAS Wild-Type Colorectal Cancer
ACTIVE NOT RECRUITING · Phase 2
-
An Investigational Scan (64Cu-Labeled M5A Antibody) in Combination With SOC Chemotherapy and Radiotherapy in Locally Advanced Rectal Cancer
RECRUITING · Early Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.